Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: A case report

Journal of Medical Case Reports

Volumn 8, Issue 1, 2014, Pages

  Ohara, Sayaka ^a   Ushijima, Tomonori ^a   Gunji, Mariko ^a   Tanai, Chiharu ^a   Tanaka, Yoshiaki ^a   Noda, Hiromichi ^a   Horiuchi, Hajime ^a   Usui, Kazuhiro ^a  

^a Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; GADOLINIUM PENTETATE; GEFITINIB; GEMCITABINE; VASCULOTROPIN;

ADENOCARCINOMA; ADULT; ARTICLE; ATELECTASIS; AUTOPSY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOMATOUS MENINGITIS; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DISORIENTATION; DYSPNEA; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; JAPANESE; LUNG SMALL CELL CANCER; MEDICAL HISTORY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; SMOKING; THORACIC CAVITY; TREATMENT RESPONSE;

EID: 84895918311     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-8-64     Document Type: Article

References (15)

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M, Science 2004 304 1497 1500 10.1126/science.1099314 15118125
2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA, N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073
3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B, N Engl J Med 2005 352 786 792 10.1056/NEJMoa044238 15728811
4. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H, PLoS Med 2005 2 73 10.1371/journal.pmed.0020073 15737014
5. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA, Science 2007 316 1039 1043 10.1126/science.1141478 17463250
6. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W, Proc Natl Acad Sci USA 2007 104 20932 20937 10.1073/pnas.0710370104 18093943
7. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S, Cancer Res 2008 68 22 9479 9487 10.1158/0008-5472.CAN-08-1643 19010923
8. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K, Br J Cancer 2006 95 1483 1489 10.1038/sj.bjc.6603466 17106442
9. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H, Radiology 2007 242 882 888 10.1148/radiol.2423051707 17229875
10. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE, J Clin Oncol 2004 22 2865 2872 10.1200/JCO.2004.12.149 15254054
11. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE, Cancer 2005 103 11 2344 2348 10.1002/cncr.21033 15844174
12. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV, Neuro Oncol 2010 12 11 1193 1199 10.1093/neuonc/noq076 20627894
13. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS, Lung Cancer 2012 77 3 556 560 10.1016/j.lungcan.2012.05.092 22677429
14. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE, J Clin Oncol 2006 24 27 4517 4520 10.1200/JCO.2006.06.6126 16983123
15. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E, Eur Respir J 2009 33 436 440 19181917